ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) Sees Significant Increase in Short Interest

ASLAN Pharmaceuticals Limited (NASDAQ:ASLNGet Rating) saw a large growth in short interest in the month of April. As of April 30th, there was short interest totalling 261,400 shares, a growth of 299.7% from the April 15th total of 65,400 shares. Based on an average trading volume of 165,000 shares, the days-to-cover ratio is currently 1.6 days. Currently, 0.4% of the shares of the company are short sold.

Several institutional investors and hedge funds have recently bought and sold shares of ASLN. Tang Capital Management LLC acquired a new stake in shares of ASLAN Pharmaceuticals in the 3rd quarter valued at approximately $1,736,000. Barclays PLC raised its holdings in ASLAN Pharmaceuticals by 169.6% during the fourth quarter. Barclays PLC now owns 508,964 shares of the company’s stock worth $570,000 after purchasing an additional 320,200 shares during the last quarter. Waterfront Wealth Inc. acquired a new position in ASLAN Pharmaceuticals during the fourth quarter worth $302,000. Affinity Asset Advisors LLC acquired a new position in ASLAN Pharmaceuticals during the third quarter worth $445,000. Finally, Point72 Asset Management L.P. acquired a new position in ASLAN Pharmaceuticals during the third quarter worth $445,000. 38.65% of the stock is owned by institutional investors and hedge funds.

Separately, Zacks Investment Research cut ASLAN Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, March 30th.

ASLAN Pharmaceuticals stock opened at $0.44 on Thursday. ASLAN Pharmaceuticals has a twelve month low of $0.42 and a twelve month high of $3.87. The stock has a 50 day moving average of $0.76 and a two-hundred day moving average of $1.07. The company has a current ratio of 9.63, a quick ratio of 9.63 and a debt-to-equity ratio of 0.81. The stock has a market capitalization of $30.69 million, a price-to-earnings ratio of -0.80 and a beta of 2.33.

ASLAN Pharmaceuticals (NASDAQ:ASLNGet Rating) last posted its quarterly earnings results on Friday, March 25th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Equities analysts predict that ASLAN Pharmaceuticals will post -0.66 earnings per share for the current year.

About ASLAN Pharmaceuticals (Get Rating)

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions.

See Also

Receive News & Ratings for ASLAN Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN Pharmaceuticals and related companies with's FREE daily email newsletter.